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ORIGINAL ARTICLE
Single centre study of using bendamustine in the treatment of B-cell
malignancies
Asif Husain Osmani, Nehal Masood

Abstract
Objective: To evaluate the experience of bendamustine in the treatment of B-cell malignancies at a tertiary care
centre.
Methods: The retrospective descriptive analysis included data of all adult patients with B-cell malignancies treated
with bendamustine from 2009 to 2011 at the Aga Khan University Hospital, Karachi. Data was analysed using SPSS
17.0. Frequencies and percentages were computed for baseline characteristics, responses and toxicities.
Results: Of the 19 patients 15 (79%) were males and 4 (21%) were females. The mean age was 59.53±12.14 (with a
range of 46-86). Eight (42%) had follicular lymphoma, 6 (32%) had mantle cell lymphoma, 2 (11%) had diffuse large
B-cell lymphoma, and 3 (16%) had chronic lymphocytic leukaemia. Four (21%) patients experienced grades 3 and 4
cutaneous toxicities. Eight (42%) patients were treated with bendamustine as first-line therapy. Six of them (75%)
were included for response evaluation; 3 (50%) had complete response, and 3 (50%) had partial response. Eleven
(58%) patients had relapsed disease out of which 3 (27.27%) had complete response, and 7 (63.63%) had partial
response, whereas 1 (9%) had disease progression.
Conclusion: Bendamustine given as monotherapy or in combination is safe and useful in the treatment of patients
with B-cell malignancies.
Keywords: Mantle cell lymphoma (MCL), Diffuse large B-cell lymphoma (DLBCL), Chronic lymphocytic leukaemia
(CLL), Follicular lymphoma (FL), Complete remission (CR), Partial response (PR), Non-Hodgkin lymphoma (NHL).
(JPMA 63: 702; 2013)

Introduction
B-cell malignancies are a diverse group of neoplasm both
in their natural history and response to treatment. They
include non-Hodgkin's lymphoma (NHL) which is the
most common haematological cancer and the sixth most
common cancer in the United States, with an estimated
65,980 new cases and 19,500 deaths occurring in 2009.1
There has been a dramatic increase in the incidence of
NHL worldwide. Though well-characterised in the West,2
in Karachi, Pakistan, NHL has been reported as the sixth
most common malignancy in both genders with an
incidence of 9.6/100,000 in males and 7.2/100,000 in
females.3 Overall institutional data reports a frequency of
6.1% for the city,4 whereas a variation is apparently
observed in the country as it has been reported as the
most common cancer in Northern Pakistani males which
may be due to the combination of environmental,
infections and genetic factors.5,6
Treatment for indolent B-cell malignancies typically
involves a combination of chemotherapy and
immunotherapy, such as cyclophosphamide, doxorubicin,
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vincristine, and prednisone (CHOP) plus rituximab.7
Alternatively, other chemotherapy regimens may be used
in
combination
with
rituximab,
including
cyclophosphamide, vincristine, and prednisone and
fludarabine-based regimens. Radiation and bone marrow
or stem cell transplantation are treatment options in
selected patients. In developing countries like Pakistan
and India, majority of the patients are treated with CHOP
regimen with favourable response rates with only few
patients receiving CD 20 (cluster of differentiation)
therapy (rituximab), due to financial reasons.6,8
Bendamustine hydrochloride is an alkylating agent that
has a unique, multifaceted mechanism of action. It
produces double-stranded and single-stranded breaks in
deoxyribonucleic acid (DNA), as do other alkylators.
However, the DNA damage induced by bendamustine is
more extensive and more durable than that produced by
cyclophosphamide, melphalan or carmustine, indicating
that bendamustine produces DNA damage by a
mechanism distinct from that of other alkylators. Further,
treatment with bendamustine impairs cell-cycle
checkpoints by inducing a 60% to 80% down-regulation
in the expression of several mitotic checkpoint genes,
including polo-like kinase 1, aurora kinase A, and cyclin
B1.9 Defects in cell-cycle checkpoints, combined with
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DNA damage, can cause cells to enter mitosis before DNA
repair has occurred. Cells that enter mitosis with
significant DNA damage undergo a form of cell death
known as mitotic catastrophe. When added to cells in
culture, bendamustine induces mitotic catastrophe; this
mechanism of inducing tumour cell death may be unique
among alkylators.10
Bendamustine received marketing approval from the
Food and Drug Administration in March 2008 for use as a
first-line treatment of chronic lymphocytic leukaemia
(CLL).11 In October 2008, it was approved for the
treatment of indolent B-cell NHL that has progressed
during or within six months of treatment with rituximab
or a rituximab-based regimen.12
Generally, indolent NHL is incurable and follows a course
of remission and relapses requiring multiple courses of
chemotherapies with or without rituximab. Therefore,
newer treatments are needed to prolong the duration of
remission and overall survival in these patients.
The efficacy of bendamustine in the treatment of indolent
NHL has been examined in several European and US
trials.9,13-16 It was also observed that this drug was
generally well tolerated and had lower incidence of
adverse effects when compared with CHOP plus
rituximab regimen.16 There is scarcity of data regarding
the experience of bendamustine from our part of the
region. The purpose of the current study was to share the
experience with this novel agent in patients with B-cell
malignancies.

Patients and Methods
The study retrospectively reviewed the records of all
patients with B-cell malignancies treated with
bendamustine from 2009 to 2011 at the Aga Khan
University Hospital, Karachi, Pakistan. Patients older than 18
years with World Health Organization (WHO) performance
status <2 were eligible if they had histologically confirmed
diagnosis of CLL, mantle cell lymphoma (MCL), follicular
lymphoma (FL) (grades 1 to 2), and diffuse large B-cell
lymphoma (DLBCL). All histopathologies of lymph node
and bone marrow were reviewed at the Histopathology
and Haematology Department. Patients were required to
have at least one of the following criteria to demonstrate
the need for treatment; impairment in haematopoiesis
(haemoglobin <11 g/dl, white blood cells <1.5×109/L and
platelets count <100×109), presence of 'B' symptoms, and
other disease-related symptoms such as bulky disease or
progressive disease.
All patients underwent pre-treatment evaluation, which
included physical examination, routine complete blood
Vol. 63, No. 6, June 2013

count (CBC), serum chemistry evaluation, computed
tomography (CT) chest scan, neck, chest, abdomen and
pelvis, bone marrow aspiration, and trephine.
CT scans were used for response evaluation in line with
literature.17 Repeat pathology was done at progression of
disease.
Bendamustine was administered at 90mg/m2 or
120mg/m2 a day for two days (30 min intravenous
infusion).14,18 Each cycle was repeated after 3 weeks as per
protocol with or without rituximab. Rituximab was
administered as intravenous infusion at a dose of
375mg/m2 a day on the first day, followed by
bendamustine on the second and third days to complete
the cycle. Prophylactic antibiotics and growth factors
were permitted depending on the patients' baseline
characteristics.
Response evaluation was done after at least 4 courses of
treatment received by each patient. However, responses
were also assessed in those patients who received less
than four courses and could not proceed with further
courses because of cost issues or adverse effects, but had
responded to the therapy. A complete remission (CR) was
defined as the disappearance of all measurable disease
(lymph node <1 cm) and return of normal counts. Normal
counts were defined as haemoglobin>11 g/dl, white
blood cell (WBC) >1.5 /mm3 and platelets >100×109 /mm3
and bone marrow showing no evidence of disease if
present before the treatment. Partial response required
more than 50% reduction of measurable disease and
more than 50% improvement of all abnormal blood
counts. Progression was defined as >25% increase in
measurable disease with one of the following criteria, (1)
corresponding enlargement of lymph node, liver or
spleen; (2) appearance of new enlarged lymph nodes; (3)
re-appearance or increasing infiltration of bone marrow;
and (4) recurrence of B symptoms. Treatment toxicities
were evaluated according to WHO grading criteria. CBC
was performed weekly.
The data was retrieved through the hospital's registration
system, and analysed using SPSS 17.0. Frequencies and
percentages were computed for baseline characteristics,
response, and toxicity to treatment.

Results
A total of 19 patients including 15 (79%) males and 4
(21%) females, with a mean age of 59.53±12.14 years
(range: 46-86 years), were part of the study. The mean age
of males was 58±12.50 and that of females was
65.75±9.946 years. According to classification of
histopathologies, 8 (42%) patients had FL, 6 (32%) had
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Table-1: Patients' characteristics.
Patients' characteristics

N (%)

Male
Mean age (years)
Histology
Follicular lymphoma
Mantle cell lymphoma
Diffuse large B-cell lymphoma
Chronic lymphocytic leukaemia
Stage
I
II
III
IV
Performance status>2
Abnormal LDH
Bone marrow involvement
Refractory to primary treatment
Prior No. of treatments
1
2
Prognostic group for lymphoma patients
Low risk (1 risk factor)
Low intermediate risk (2 risk factor)
High intermediate (3 risk factor)
High risk (4-5 risk factor)
Prognostic group for follicular
Low risk (0-1 risk factor)
Intermediate risk (2 risk factor)
Poor risk (3-5 risk factor)

15 (79%)
59.53±12.14 (range 46-85)
8 (42%)
6 (32%)
2 (11%)
3 (16%)
2 (11%)
1 (05%)
0
16 (84%)
0
7 (39%)
11 (58%)
11 (58%)

In a total of 98 courses of bendamustine (range: 2-11), 13
(68.42%) patients received a dose of 90mg/m2 and 6
(31.57%) patients received a dose of 120mg/m2 in two
consecutive days. Fourteen (73.68%) patients received
rituximab along with bendamustine. The dose of
bendamustine varied according to physicians' preference.

Complete remission

Partial remission

No response

2 (25%)
4 (67%)
0
0

4 (50%)
2 (33%)
1 (50%)
3 (100%)

2 (25%)
0
1 (50%)
0

FL (n=8)
MCL (n=6)
DLBCL(n=2)
CLL(n=3)

FL: Follicular lymphoma; MCL: Mantle cell lymphoma; DLBCL: Diffuse Large B-cell Lymphoma; CLL:
Chronic Lymphocytic Leukaemia.

Table-3: Evaluation of treatment-related toxicity.
Adverse Effects

Leucopenia
Thrombocytopenia
Anaemia
Nausea/vomiting
Allergic/skin reaction
Cardiotoxicity
Neurotoxicity
Alopecia

Grades
0
14
8
13
13
14
19
18
19

1
3
2
1
4
1
0
1
0

2
1
3
4
2
0
0
0
0

3
0
4
1
1
3
0
0
0

Of the patients, 11 (58%) were treated for relapsed
disease, of which 10 (90.90%) patients had stage IV
disease. Prior treatment regimens included RCHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone) in 7 (36.84%) patients, RCVP (rituximab,
cyclophosphamide, vincristine, prednisone) in 5 (26/31%)
cases and ICE (ifosfamide, etoposide, carboplatin), hyper
CVAD protocol (Hyperfractionated cydophosphamide,
vincristine, doxorubicin and dexamethasone) and
fludarabine base regimen in 1 (5/26%) patient each.
Seven (36.84%) patients were treated with bendamustine
as second-line and 4 (21%) patients were treated as thirdline therapy.
In patients with lymphoma, according to International
Prognostic Index (IPI), 5 (31%) were in low and lowintermediate prognostic index, and 11 (69%) were in highintermediate and high-risk group. FL was also classified
according to follicular lymphoma international prognostic
index (FLIPI) in 8 (42%) patients; 6 (75%) had poor risk,
while 2 (25%) patients had low risk.

7 (64%)
4 (36%)
16
3 (19%)
2 (12%)
8 (50%)
3 (19%)
8
2 (25%)
0
6 (75%)

Table-2: Evaluation response in patients treated with bendamustine.
Entity

MCL, 2 (11%) had DLBCL, and 3 (16%) had CLL. According
to staging classification, 2 (11%) patients had stage I
disease, 1 (5%) patient had stage II disease, and 16 (84%)
had stage IV disease (Table-1).

4
1
2
0
0
1
0
0
0

Eight (44%) patients were treated with bendamustine as
first-line regimen. Six of them (75%) were included for
response evaluation; 3 (50%) patients had complete
response (CR) and 3 (50%) had partial response (PR). Two
(25%) patients were still having treatment so they were
not assessed for response. Eleven (58%) patients had
relapsed disease. Of them 3 (27.27%) had CR and 7
(63.63%) had PR, while 1 (9%) patient had progression.
Six (31.57%) patients were with MCL; 4 (67%) had CR and
2 (33%) had PR. Eight (42%) patients were with FL; 2 (25%)
had CR and 4 (50%) had PR while 2 (25%) patients were
still receiving treatment and their evaluations were not
done. One (50%) patient with DLBCL, and 3 (100%) with
CLL had PR, whereas 1 (50%) patient with DLBCL had
progression (Table-2).
A total of 98 treatment cycles were evaluated for toxicity
(Table-3). Cutaneous grades 3 and 4 toxicities were
experienced in four (21%) patients, of which 3 (75%) had
generalised erythematous rash, and 1 (25%) had
J Pak Med Assoc
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reactivation of dermatomal herpes zoster during therapy,
so the treatment was discontinued. Haematological
toxicities were most frequently reported, with grades 3 and
4 thrombocytopenia in 6 (31%) patients, grade 3 anaemia
in 1 (5.26%) patient, and grade 4 leucopenia in 1 (5.26%)
patient. Non-haematologic toxicities were generally mild.
Grades 1 and 2 nausea and vomiting were experienced in 7
(37%) patients. None of the patients experienced alopecia.
There were no treatment-related deaths.

Discussion
This report represents the first study regarding the
experience of bendamustine in indolent B-cell
malignancies in Pakistan. Majority of the patients in the
population were of older age group as bendamustine has
been observed to be well tolerated even in patients above
80 years of age with favourable responses and tolerability
profile and, more so, the toxicity of bendamustine was
low in this age group.17
Lymphoma with indolent histologies is often
asymptomatic in the early stage and usually advanced at
the time of detection. In the present study, 84% of the
patients had stage IV disease and majority of them fell in
high-risk category according to IPI. Bendamustine has
been effective in refractory NHL. A recent US phase II trial
of 76 patients with NHL treated with bendamustine had
high objective response rates (ORR, 77% including 15%
CR).13 Another study observed the efficacy of
bendamustine and rituximab in patients with relapsed
indolent B-cell and MCL.14 Eligible patients received up to
three prior treatments; prior rituximab was allowed as
long as the patients' disease was not refractory to
rituximab. The ORR to treatment was 92%, including 41%
CR.14 Majority of the study's population had relapsed
disease and all of them received rituximab as prior
therapy, but were not refractory. The overall response rate
was 91%, including 27% CR.
Majority of our patients had a relapsed and stage IV
disease, yet the CR was much higher. This was because of
the limited number of patients in our study. The results, as
such, cannot be generalised. But this was an intriguing
finding of excellent response which needs to be explored
in prospective studies. We, as a population, are very
diverse with different epigenetic factors and this could be
an alternate explanation for this amazing response.
However, these are only assumptions which need further
confirmation. Our study can be considered as a
preliminary report on the subject with detailed
comprehensive ones to follow in the future.
As it was not a response evaluation study therefore
patients were not matched stage-to-stage. The numbers
Vol. 63, No. 6, June 2013
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were limited and the purpose was to share the experience
and course of disease when treated with either
bendamustine alone or with rituximab combination.
MCL generally experiences a more aggressive course, with
rapid disease progression. Therapeutic options for this
group are limited. Many patients quickly become refractory
to treatment. In a recent retrospective study evaluating the
efficacy of bendamustine in a small population of MCL
treated with upfront bendamustine, patients had 60% CR
and 40% PR.14 Similarly, a large German phase III trial
showed 66% ORR with 22% CR in one study and 94% ORR
with 41% CR in another trial.16,19 Fifty per cent of the study's
MCL patients had refractory disease and most of them had
advanced disease. CR was seen in 67% of the patients. One
patient initially had PR with rituximab bendamustine after
receiving 6 cycles, but after 9 months, had progression of
disease. He was re-treated with the same regimen and had
CR after 5 more cycles.
The efficacy and safety of bendamustine has been
observed in the first-line setting in multiple studies.15,21
The patients treated upfront with rituximab and
bendamustine in one study had CR in 54% in a small
population.17 In this study, CR was observed in 3 patients,
and PR in the other 3 patients.
Regarding the toxicity profile of bendamustine, most
frequently observed were the severe cutaneous reactions,
which is in line with literature.21 These cutaneous
reactions were treated by steroid and anti-histamine and
they required dose reduction in the subsequent cycles.
One patient discontinued treatment because of the reactivation of herpes zoster. She was treated with anti-viral
and analgesics and eventually recovered. A similar case
was also reported in a recent study.22
As with all other cytotoxic therapies, bendamustine
suppresses bone marrow functions, commonly resulting
in thrombocytopaenia, neutropaenia and anaemia. In this
study population, grades 3 and 4 thrombocytopaenia was
seen in 31% of the patients, as previously reported by
other studies.9,23 One patient was admitted with febrile
neutropaenia, whereas another patient had grade 3
anaemia; these findings were consistent with literature.22
The toxicity profile of rituximab and bendamustine is
more beneficial in comparison with the combination of
rituximab with CHOP-like therapy.16 Treatment-related
nausea and vomiting were generally mild and none of the
patients had alopecia.
The objective of the current study was not to assess the
tolerability or response; hence comparison with standard
of care. It was only to share institutional experience in a
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limited series of patients.

13.

Conclusion
Bendamustine given as monotherapy or in combination
with rituximab is safe and useful in the treatment of
patients with B-cell malignancies.
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